; (IV) demonstrating clinical expertise in the management of CCM and appointing a director and support staff, including a trainee and patient representative, for CCM research programming; (V) treating a sufficient number of eligible patients for participation with particular focus on unique subpopulations, such as patients with the common Hispanic mutation, Ashkenazi Jewish mutation, or CCM3 gene mutation carriers; and (VI) maintaining a telehealth infrastructure to support and provide clinical consultation for remote and underserved communities. (3) Participation centers (A) In general The Director of NIH shall identify and support the development of approximately 6 to 10 clinical and research participation centers to facilitate medical research to develop a cure for CCM and enhance the medical care of individuals with CCM, in partnership with the coordinating centers under paragraph (2) and other national and international entities, as appropriate. (B) Eligibility To qualify for selection as a participation center under subparagraph (A), an entity shall— (i) at the time of selection— (I) be affiliated with an established research network of the National Institutes of Health; and (II) have the potential to participate in a multisite clinical drug trial with respect to CCM; (ii) demonstrate— (I) an institutional infrastructure capable of hosting a clinical trial site and facilitating translational projects and collaborations for clinical trials; (II) the capacity to maintain communication with other major CCM research and care institutions internationally for information sharing and coordination of research activities, especially through health information technology; and (III) clinical expertise in CCM disease management or complete the CCM clinical training program under subsection (c)(4)